FIGURE 1



Probability
1.00
0.75
0.50
0.25
0.00
p=0.1177
Placebo
BDP
0 5 10 15 20 25 30 35 40 45 50 55
Days since randomization
1-10 11-20 21-30 31-40 41-50
BDP 8/62 3/50 4/47 2/42 1/39
Placebo 4/67 8/61 9/50 4/41 5/36
(#events/#at risk)

FIGURE 2



Probability
1.00
0.75
0.50
0.25
0.00
p=0.0226
Placebo
BDP
0
10
20
30
40
50
60
70
80
90
Days since randomization
1-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80
BDP 8/62 3/50 4/47 2/42 1/39 1/37 2/35 1/30
Placebo 4/67 8/61 9/50 4/41 5/36 1/30 4/29 4/23
(#events/#at risk)

FIGURE 3




Probability
1.00
0.75
0.50
0.25
0.00
BDP
Placebo
p=0.0527
0
6
12
18
24
30
36
42
Months since randomization
0-6 7-12 13-18 19-24 25-30 31-36 37-42
BDP 6/61 6/54 1/17 0/7 0/5 0/4 0/0
Placebo 16/66 6/47 2/16 0/8 0/7 0/7 0/2
(#events/#at risk)

FIGURE 4



CS = corticosteroids expressed as prednisone equivalent

SD = study drug tablets

* On Study Day 11-17 rapid prednisone taper begins if on Study Day 10 the investigator judges the patient's GVHD to be controlled.